Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients

Nephrology Dialysis Transplantation

Volumn 25, Issue 3, 2010, Pages 976-984

  Han, Seung Jin ^a,b   Hur, Kyu Yeon ^c   Kim, Yu Seun ^d   Kang, Eun Seok ^d   Kim, Soon Il ^d   Kim, Myoung Soo ^d   Kwak, Jung Young ^e   Kim, Dae Jung ^a   Choi, Sung Hee ^f   Cha, Bong Soo ^d   Lee, Hyun Chul ^b,d  

^a Ajou University School of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

Author keywords

Carotid intima media thickness; Insulin resistance; Pioglitazone; Renal allograft

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; PIOGLITAZONE; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; ATHEROSCLEROSIS; CALORIC INTAKE; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; FAMILY HISTORY; FEMALE; GRAFT RECIPIENT; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INTIMA; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; ADULT; ATHEROSCLEROSIS; CAROTID ARTERIES; DISEASE PROGRESSION; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77649209056     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp567     Document Type: Article

References (38)

1. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-165
2. Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004; 18: 596-604
3. Ducloux D, Bourrinet E, Motte G, et al. Antiphospholipid antibodies as a risk factor for atherosclerotic events in renal transplant recipients. Kidney Int 2003; 64: 1065-1070
4. Cofan F, Arias M, Nunez I, et al. Impact of carotid atherosclerosis as assessed by B-mode ultrasonography on the evolution of kidney transplantation. Transplant Proc 2007; 39: 2236-2238
5. Toz H, Duman S, Altunel E, et al. Intima media thickness as a predictor of atherosclerosis in renal transplantation. Transplant Proc 2004; 36: 156-158
6. Malyszko J, Malyszko JS, Hryszko T, et al. Renal transplant recipients with coronary artery disease exhibit impairment in fibrinolysis and structural changes in carotid arteries. Transpl Int 2005; 18: 256-259
7. Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004; 4: 2135-2138
8. Voytovich MH, Simonsen C, Jenssen T, et al. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 2005; 20: 413-418
9. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-2531
10. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931
11. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456
12. Hjelmesaeth J, Flyvbjerg A, Jenssen T, et al. Hypoadiponectinemia is associated with insulin resistance and glucose intolerance after renal transplantation: impact of immunosuppressive and antihypertensive drug therapy. Clin J Am Soc Nephrol 2006; 1: 575-582
13. Bakkaloglu SA, Soylemezoglu O, Buyan N, et al. Adiponectin levels and arteriosclerotic risk factors in pediatric renal transplant recipients. Pediatr Transplant 2006; 10: 187-192
14. Kim SH, Lee SJ, Kang ES, et al. Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism 2006; 55: 1053-1059
15. Yokoyama H, Aoki T, Imahori M, et al. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int 2004; 66: 448-454
16. Marcucci R, Zanazzi M, Bertoni E, et al. Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients. Transplant Proc 2005; 37: 2491-2492
17. Kang ES, Kim HJ, Ahn CW, et al. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract 2005; 69: 151-159
18. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23: 295-301 (Pubitemid 30131733)
19. Hjelmesaeth J, Midtvedt K, Jenssen T, et al. Insulin resistance after renal transplantation: impact of immunosuppressive and antihyper-tensive therapy. Diabetes Care 2001; 24: 2121-2126
20. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27: S5-S10
21. Nafar M, Khatami F, Kardavani B, et al. Atherosclerosis after kidney transplantation: changes of intima-media thickness of carotids during early posttransplant period. Urol J 2007; 4: 105-110
22. Raine AE, Margreiter R, Brunner FP, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7: 7-35 (Pubitemid 23049872)
23. Suwelack B, Witta J, Hausberg M, et al. Studies on structural changes of the carotid arteries and the heart in asymptomatic renal transplant recipients. Nephrol Dial Transplant 1999; 14: 160-165
24. Cofan F, Gilabert R, Zambon D, et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplant Proc 2002; 34: 384-388
25. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573
26. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301
27. Cueto-Manzano AM, Morales-Buenrostro LE, González-Espinoza L, et al. Markers of inflammation before and after renal transplantation. Transplantation 2005; 80: 47-51
28. Oflaz H, Pusuroglu H, Genchallac H, et al. Endothelial function is more impaired in hemodialysis patients than renal transplant recipients. Clin Transplant 2003; 17: 528-533
29. Chen J, Hamm LL, Fonseca V, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14: 469-477
30. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583-592
31. Kim SH, Abbasi F, Chu JW, et al. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005; 54: 2447-2452
32. Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allo-graft recipients. Diabetes Care 2007; 30: 609-615
33. Hagen M, Hjelmesaeth J, Jenssen T, et al. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 2003; 18: 2154-2159
34. Nam JH, Mun JI, Kim SI, et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001; 71: 1417-1423
35. Nowak SN, Edwards DJ, Clarke A, et al. Pioglitazone: effect on CYP3A4 activity. J Clin Pharmacol 2002; 42: 1299-1302
36. Pereira MG, Camara NO, Campaholle G, et al. Pioglitazone limits cyclosporine nephrotoxicity in rats. Int Immunopharmacol 2006; 6: 1943-1951
37. Chung BH, Li C, Sun BK, et al. Rosiglitazone protects against cyclo-sporine-induced pancreatic and renal injury in rats. Am J Transplant 2005; 5: 1856-1867
38. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000; 13: 4-8